Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

36.87USD
9:00pm BST
Change (% chg)

$-2.22 (-5.68%)
Prev Close
$39.09
Open
$39.02
Day's High
$39.39
Day's Low
$36.77
Volume
146,088
Avg. Vol
188,318
52-wk High
$60.98
52-wk Low
$36.19

Omenn, Gilbert 

Dr. Gilbert S. Omenn, M.D., Ph.D., is an independent Director of the Company. He has been a Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He leads the global Human Proteome Project. He serves on the Council of the National Academy of Medicine and the Community Preventive Services Task Force of the Centers for Disease Control and Prevention (CDC). Previously, Dr. Omenn was Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs; Professor of Medicine and of Environmental Health, and Dean of the School of Public Health and Community Medicine, at the University of Washington; Associate Director of the White House Office of Science & Technology Policy and of the Office of Management and Budget; and a Howard Hughes Medical Investigator. He has served on the National Cancer Advisory Board, National Heart, Lung and Blood Institute Advisory Council, Scientific Management Review Board of the NIH, and the Director's Advisory Committee for the CDC. Dr. Omenn earned his Bachelor's degree summa cum laude from Princeton University, his M.D. magna cum laude from Harvard Medical School, and his Ph.D. in genetics from the University of Washington. Dr. Omenn serves on the boards of Galectin Therapeutics, Inc. (NASDAQ: GALT) and Oncofusion Therapeutics, Inc. Previously, Dr. Omenn was a director of Amgen, Inc. (NASDAQ: AMGN) and Rohm & Haas Company.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 45,222
Fiscal Year Total, USD 389,068

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --